What's in a Name? Fewer letters for one...
Back in the old days, I was too lame to know I could get a short domain name. Then when I caught a clue, many good ones were taken. I found lymphomainfo.net and lymph.net. You can guess which I kept and which I let lapse (lymph.net is now a cover site for a useless Goggle ads based site - sad).
Well the other day I saw lymphoma.info for sale. I had tried to get it when the .info group was opened but I lost the lottery. Some guy in Canada bought it and never used it. Now he's selling it on a name website listed as "Make Offer". Well, he'll only start bidding at $25,000.00. It made me mad. I told him I'm a blogger, not a pharmaceutical company. No sympathy.
It made me mad enough to be creative. Lots of top level domains - what is .ma? Of course, Morocco.... Well registering a domain there is more expensive than in the US but I thought I'd try. And lympho.ma was born!
So now you can type in your browser lympho.ma instead of the/ -- or to get to this blog lympho.ma/blog -- much shorter.
Do you have an opinion on one domain name or the other - leave a comment, if you like.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
